Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07399821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

Study acronym: GLOW-FISH
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
Trial Details
NCT Number NCT07399821
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Conditions
(from sponsor)		 Neuroblastoma
Related terms Neuroblastoma
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov